Powered by science Driven by passion

John W. Hadden II is Chief Executive Officer and co-founder of ViroCell Biologics. A successful serial entrepreneur, John’s passion for science and medicine and business acumen have enabled him to meet the challenges of the journey from laboratory to clinic to marketing authorization with a range of life science companies.

In addition to his board membership with ViroCell Biologics, John has substantial board and governance experience with for-profit companies, as well as non-profit organizations.  

John has extensive experience shaping and executing strategy, building strong partnerships, managing transformational change and leading genuinely diverse organizations.  

Farzin Farzaneh, PhD, FRCPath, FRSB, is Chief Scientific Officer of ViroCell Biologics and serves as a member of the Board of Directors. He is also Chair of Molecular Medicine at King’s College London and Trans-campus Professor of Molecular Medicine at Technical University of Dresden, Germany.

He established the Rayne Cell and Gene Therapy Suite (RCTS) for the GMP manufacture of Investigational Medicinal Products (IMP) and Advanced Therapy Medicinal Products (ATMP) at King’s in 2001. This facility has produced the largest number of viral vectors for gene therapy based clinical studies in Europe. He is also Member of the MHRA Commission on Human Medicines: Clinical Trials, Biologicals & Vaccines (CTBV) Expert Advisory Group.

Brian Collins is Chief Financial Officer of ViroCell Biologics. He brings over thirty years of financial and operations leadership experience from working at large corporations, private equity and not-for-profits in the UK, Switzerland, and the US. 

Most recently, Brian was CFO at the Cell and Gene Therapy Catapult, an independent innovation and technology organization committed to the advancement of cell and gene therapies. He oversaw the Corporate Services team which included Finance, HR, IT, Procurement as well as the Operational Excellence program.

Toni Trevett, FCIPD, is Chief People Officer at ViroCell Biologics. She has spent many years working and consulting in people management and has held leadership roles in large corporations in the UK, including as an HR Director within the BAA Plc group. 

Toni has worked in organizations in various industries including Talbot Underwriting Ltd., Lewis Silkin LLB, AAT, BAT Plc, Stihl, and Featurespace, among others.

Nick Maishman is Chief Operating Officer at ViroCell Biologics. He brings over thirty years of commercial manufacturing and operations management and leadership experience. He has served as Site Head, General Manager, VP, and COO roles with pharmaceutical, biotech, vaccine and CDMO companies such as GlaxoSmithKline, Pfizer, Valneva, Alexion and Recipharm. He has worked in UK, Ireland, France, Greece, Austria, and USA.

Nick has significant experience leading the construction and start-up of new manufacturing sites, gaining regulatory approval for CT and Commercial GMP manufacturing, including for complex biologics such as monoclonal antibodies and vaccines, as well as antibiotic and antiviral medicines. His regulatory experience includes contributing to new product submissions to FDA and EMA, and hosting site inspections from FDA, MHRA, European and International regulatory authorities.